

| PATIENT INFORMATION | | | | |
|---|--|---|-----------------------------------|--|
| Patient Name | Male <input type="checkbox"/> Female <input type="checkbox"/> | Allergies | NKDA | |
| Date of Birth | SSN# | Weight | Kg Lb | Date / / |
| Address | City | State/Zip | | |
| Phone # (Home) | Work # | Email Address | | |
| Caregiver | Case Manager | | | |
| INSURANCE INFORMATION | | | | |
| Primary Insurance | | Policy Holder | | |
| Group # | Policy # | Phone # | | |
| Secondary Insurance | Policy # | Phone # | | |
| DIAGNOSIS/MEDICAL INFORMATION (PLEASE SPECIFY PRIMARY & SECONDARY DIAGNOSIS) | | | | |
| <input type="checkbox"/> K50.90 Crohn's Disease NOS | <input type="checkbox"/> K50.0 Crohn's small intestine | <input type="checkbox"/> K50.1 Crohn's large intestine | | |
| <input type="checkbox"/> Other ICD-10 | Severity Type: | <input type="checkbox"/> Mild | <input type="checkbox"/> Moderate | <input type="checkbox"/> Severe <input type="checkbox"/> Fistulizing |
| Does the patient have CHF (NYHA Class III/IV)? <input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Induction therapy <input type="checkbox"/> Maintenance therapy | | | | |
| Does patient have clinically important active infection? <input type="checkbox"/> Yes <input type="checkbox"/> No | | | | |
| TB skin test result <input type="checkbox"/> Negative <input type="checkbox"/> Positive Date: / / | | | | |
| Failure of (check all that apply & list dosing/therapy below): | | | | |
| <input type="checkbox"/> Mesalamine <input type="checkbox"/> Corticosteroids <input type="checkbox"/> Mercaptopurine <input type="checkbox"/> Azathioprine <input type="checkbox"/> Sulfasalazine <input type="checkbox"/> Methotrexate | | | | |
| <input type="checkbox"/> Other <input type="checkbox"/> None | | | | |
| Is patient new to therapy? <input type="checkbox"/> Yes <input type="checkbox"/> No If no, date therapy began / / Date of Diagnosis: / / | | | | |
| PREVIOUS MEDICATIONS (PLEASE SPECIFY DOSAGE & TIME ON THERAPY) | | | | |
| Medication Strength & Dose | Dates of Therapy | | Reason for Discontinuing | |
| | | | | |
| | | | | |
| PRESCRIPTION INFORMATION | | | | |
| Medication | Strength | Directions | Quantity | Refills |
| <input type="checkbox"/> Cimzia® | <input type="checkbox"/> 200 mg/1ml. Prefilled Syringe <input type="checkbox"/> 200 mg vial | <input type="checkbox"/> Induction Dose. Inject SubQ 400 mg (2 vials) on day 1, and at weeks 2 and 4 <input type="checkbox"/> Maintenance Dose. Inject SubQ 400 mg (2 vials) every 4 weeks | 3 kits (6 vials) | |
| <input type="checkbox"/> Humira PFS® <input type="checkbox"/> Humira Pen® | <input type="checkbox"/> 40 mg | <input type="checkbox"/> SubQ every other week <input type="checkbox"/> _____ | | |
| <input type="checkbox"/> Remicade® (infliximab) | <input type="checkbox"/> 5 mg/kg <input type="checkbox"/> ____ mg/kg | <input type="checkbox"/> IV @ 0, 2, & 6 weeks (induction) <input type="checkbox"/> IV every 6 weeks (maintenance for AS)/(maintenance for PsA) <input type="checkbox"/> IV every ____ weeks (Must be dispensed to physician's office or infusion center) | | |
| <input type="checkbox"/> Simponi PFS® <input type="checkbox"/> Simponi Pen® | <input type="checkbox"/> 50 mg <input type="checkbox"/> 100 mg | <input type="checkbox"/> Induction Dose. 200 mg (2 x 100 mg) SubQ on Week 0 then 100 mg SubQ at 2 weeks end <input type="checkbox"/> Maintenance Dose. 100 mg SubQ every 4 weeks | 3 Syringes 1 Syringe | |
| <input type="checkbox"/> Tysabri® | | | | |
| DELIVERY INSTRUCTIONS | | | | |
| <input type="checkbox"/> Physician's Office <input type="checkbox"/> Patient's Home <input type="checkbox"/> Other | | | | |
| Address | | Phone # | | |
| City/State/Zip | | Date Medication Needed / / | | |
| PHYSICIAN CONTACT INFORMATION & AUTHORIZATION | | | | |
| Physician Name | | Phone | Fax | |
| Address | | City/State/Zip | | |
| NPI # | DEA # | Office Contact | | |
| Physician Signature (signature required to process prescription) | | | | Date |